(2018), Cell Metab 27(3), PubMed 29514064 Statistics from preclinical literature NAD+ (nicotinamide adenine dinucleotide), a key cofactor of redox reactions and substrate for sirtuins, PARP, CD38 , molecular weight 663.43 g/mol (not a peptide, but traditionally included in peptide research collections) Identified by Arthur Harden (Nobel Prize 1929) in 1906 as a coferment Standard experimental intravenous dose in clinical studies: 250750 mg/day for 410 days (Grant 2019, Conlon & Bird 2020) NAD+ levels decline with age by ~50 % in various tissues between ages 30 and 80 (Massudi 2012) Mechanism of supplementation: direct intravenous repletion, or precursors NR (nicotinamide riboside), NMN (nicotinamide mononucleotide) that are converted to NAD+ via NAMPT/NRK enzymes In Conlon & Bird (2020, n=11): NAD+ IV infusion 750 mg/day for 6 days raised plasma NAD+ by ~40 % over baseline NR and NMN are registered in the USA as dietary supplements (NDI status)
This cardiovascular evidence represents a qualitative difference between the compounds: semaglutide is proven to reduce heart attacks and strokes, while AOD-9604 has not been shown to produce clinically meaningful benefits in any domain
Even when refrigerated, its potency will decline over time
Other considerations Other precautions may be needed in people with certain health conditions
Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver
